Financials Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:12 2024-07-19 EDT 5-day change 1st Jan Change
22.45 HKD -0.66% Intraday chart for Shanghai Henlius Biotech, Inc. -0.88% +61.51%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 19,793 21,477 9,765 6,144 6,866 11,418 - -
Enterprise Value (EV) 1 18,101 22,196 9,765 6,144 6,866 11,418 11,418 11,418
P/E ratio -20.7 x -21 x -9.82 x -8.83 x 12.6 x 19.2 x 15.8 x 13.8 x
Yield - - - - - - - -
Capitalization / Revenue 218 x 36.6 x 5.8 x 1.91 x 1.27 x 1.94 x 1.77 x 1.54 x
EV / Revenue 218 x 36.6 x 5.8 x 1.91 x 1.27 x 1.94 x 1.77 x 1.54 x
EV / EBITDA -25.7 x -25 x -23.3 x -19.8 x 6.72 x 10.5 x 9.41 x 8.1 x
EV / FCF -14.5 x -17.8 x -9.38 x - 12 x 30.5 x 32 x 13.4 x
FCF Yield -6.89% -5.62% -10.7% - 8.36% 3.28% 3.13% 7.47%
Price to Book 4.53 x 6.71 x 4.25 x 3.75 x 3.13 x 4.04 x 3.44 x 2.84 x
Nbr of stocks (in thousands) 543,495 543,495 543,495 543,495 543,495 543,495 - -
Reference price 2 36.42 39.52 17.97 11.30 12.63 21.01 21.01 21.01
Announcement Date 3/23/20 3/26/21 3/16/22 3/31/23 3/21/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 90.93 587.6 1,682 3,215 5,395 5,875 6,451 7,411
EBITDA 1 -768.7 -857.8 -420 -310.6 1,021 1,083 1,213 1,410
EBIT 1 -851.2 -993.6 -620.2 -323.8 662 751 851.2 1,075
Operating Margin -936.09% -169.09% -36.86% -10.07% 12.27% 12.78% 13.2% 14.51%
Earnings before Tax (EBT) 1 -874.8 -993.5 -956.7 -693.9 569.6 662.5 804.6 953
Net income 1 -875.5 -993.5 -984.1 -695.3 546 594.4 709.7 887.2
Net margin -962.8% -169.09% -58.49% -21.63% 10.12% 10.12% 11% 11.97%
EPS 2 -1.760 -1.880 -1.830 -1.280 1.000 1.097 1.327 1.521
Free Cash Flow 1 -1,364 -1,207 -1,041 - 574.2 374 357 853
FCF margin -1,500.51% -205.34% -61.86% - 10.64% 6.37% 5.53% 11.51%
FCF Conversion (EBITDA) - - - - 56.23% 34.54% 29.43% 60.49%
FCF Conversion (Net income) - - - - 105.17% 62.92% 50.31% 96.15%
Dividend per Share - - - - - - - -
Announcement Date 3/23/20 3/26/21 3/16/22 3/31/23 3/21/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - 719 - - - - - -
Net Cash position 1,692 - - - - - - -
Leverage (Debt/EBITDA) - -0.8386 x - - - - - -
Free Cash Flow 1 -1,364 -1,207 -1,041 - 574 374 357 853
ROE (net income / shareholders' equity) -30.2% -27.6% -35.8% -35.4% 28.5% 27% 28.7% 28.3%
ROA (Net income/ Total Assets) - -16.1% - - 5.8% 6.9% 6.05% 6.4%
Assets 1 - 6,169 - - 9,414 8,614 11,730 13,862
Book Value Per Share 2 8.050 5.890 4.230 3.010 4.030 5.200 6.100 7.400
Cash Flow per Share - -1.230 - - - - - -
Capex 1 289 557 460 585 474 675 602 588
Capex / Sales 317.77% 94.79% 27.37% 18.2% 8.78% 11.48% 9.33% 7.93%
Announcement Date 3/23/20 3/26/21 3/16/22 3/31/23 3/21/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
21.01 CNY
Average target price
18.79 CNY
Spread / Average Target
-10.56%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. Financials Shanghai Henlius Biotech, Inc.